Tenaya Therapeutics (TNYA) Net Equity Issued and Repurchased (2020 - 2025)

Tenaya Therapeutics' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $104.2 million for Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased rose 122.73% year-over-year to $104.2 million; the TTM figure through Mar 2026 stood at $104.2 million (up 11295.08% YoY), while the FY2025 annual figure was $105.1 million, up 124.68% from the prior year.
• Net Equity Issued and Repurchased for Q4 2025 stood at $104.2 million, up from -$47.9 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $104.2 million in Q4 2025, with the low at -$47.9 million in Q3 2025.
• The 3-year median for Net Equity Issued and Repurchased is $20.0 million (2021), against an average of $19.1 million.
• Peak annual rise in Net Equity Issued and Repurchased reached 202.41% in 2025, while the deepest fall reached 98.05% in 2025.
• Tenaya Therapeutics' Net Equity Issued and Repurchased stood at -$5000.0 in 2021, then soared by 935340.0% to $46.8 million in 2024, then jumped by 122.73% to $104.2 million in 2025.
• Business Quant data shows TNYA's Net Equity Issued and Repurchased at $104.2 million in Q4 2025, -$47.9 million in Q3 2025, and $47.9 million in Q2 2025.